Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1

Patients must have measurable disease based on RECIST 1.1

Measurable disease by RECIST v1.1

Radiographically measurable or evaluable disease per RECIST v1.1.

Patients must have measurable disease as defined by RECIST v. 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration

Measurable disease (defined by RECIST v. 1.1) or evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease related in the setting of cancer antigen [CA]25 >= 2 x upper limit of normal [ULN])

Have measurable disease based on RECIST 1.1 including at least two cancerous deposits; at least one deposit must be RECIST measurable while at least one deposit must meet criteria for SBRT; non-radiated tumor will be identified prior to randomization on the protocol

Measurable disease by RECIST 1.1 (Phase 2 only)

Measurable disease as defined by RECIST v1.1

Measurable or non-measurable disease per RECIST version (v)1.1

Subject in Phase 2 only: must have measurable disease per RECIST 1.1.

Have at least one measurable area of disease based on RECIST 1.1 within the previously radiated field

Measurable disease according to RECIST criteria (Version 1.1)

Patient much have measurable disease as defined by RECIST 1.1

4. Measurable disease per RECIST v1.1 and irRECIST;

Measurable disease as defined by RECIST v1.1

Measurable disease by RECIST v1.1 with at least one measurable target lesion

Measurable disease per RECIST 1.1.

Has measurable disease assessed by the investigator based on RECIST version 1.1.

Have measurable disease based on RECIST 1.1

Measurable or non-measurable, but evaluable disease using RECIST v1.1

Dose Escalation: Evaluable or measurable disease according to RECIST v1.1 Expansion Cohort (additional 30 patients) Measurable disease according to RECIST v1.1.

Measurable disease based on RECIST 1.1

Indication A only: at least 2 measurable lesions as defined per modified RECIST 1.1 within 28 days prior to the first dose of AMG 757

Measurable disease by RECIST v1.1 with at least 1 measurable lesion;

Cohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Evaluable or measurable disease by RECIST 1.1

Cohort A Dose Expansion (Ribociclib + PDR001): Measurable disease by RECIST 1.1 is required

Expansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Measurable disease by RECIST 1.1 is required

Has measurable disease based on RECIST 1.1 as assessed by the central imaging vendor.

Measureable disease as defined by the RECIST 1.1.

Have measurable disease based on RECIST 1.1

Patients must have measurable or evaluable disease per RECIST 1.1 criteria

Measurable disease per RECIST 1.1.

Have at least one measurable disease based on RECIST 1.1

Subjects must have at least one measurable target lesion according to RECIST version (v)1.1

One or more metastatic tumors measurable per RECIST Criteria

Measurable disease, as defined by RECIST v1.1

Measurable disease by RECIST 1.1

At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.

PART I: participants are required to have only evaluable disease (disease that is visible on imaging studies but does not meet RECIST criteria for measurable disease)

Subject has at least one measurable lesion per RECIST v1.1.

One or more measurable or nonmeasurable evaluable lesions per RECIST 1.1.

Measurable disease as per RECIST v1.1 criteria

Measurable disease via RECIST

Patient must have at least one measurable site of disease as defined by RECIST version (v)1.1, determined by investigator review

Subject must have measurable neoplastic disease according to the RECIST v1.1;

Measurable disease according to RECIST Version 1.1

RANDOMIZED PHASE II CLINICAL TRIAL: Have measurable clinical disease: Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST (version v1.1)

Patients must have measurable or evaluable disease as defined per the RECIST v1.1 except patients with mCRPC.

Must have at least 1 site of measurable disease by RECIST criteria, by version 1.1

Measurable disease by RECIST v1.1

Measurable disease according to RECIST version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; NOTE: A subject with prior brain metastasis may be considered if they comply with inclusion criteria below

Measurable disease as defined by RECIST

One site of measurable disease by RECIST 1.1

Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.

For Part G, H, and I: Have measureable disease as defined by RECIST 1.1.

Patients with measurable disease must have at least one target lesion as defined by RECIST 1.1” to be used to assess response on this protocol

At least one measurable lesion as defined by RECIST version (v)1.1 criteria; previously irradiated lesions are not measurable unless the lesion has demonstrated clear progression after radiation

Participants must have measurable disease (RECIST 1.1)

Patients in the dose escalation phase of the study must have measurable or evaluable disease according to RECIST 1.1 criteria

Measurable disease as defined by RECIST 1.1 is required (Part 2)

Subjects must have measurable lesions (according to standard RECIST 1.1).

Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v.1.1.

Baseline measurable disease as measured by RECIST v1. 1.

Participants must have measurable extracranial disease as defined by RECIST 1.1

Measurable disease per RECIST version (v)1.1.

Has measurable disease per RECIST 1.1 as assessed by the investigator/radiology

Measurable disease per RECIST v1.1

One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.

Presence of measurable disease per RECIST v1.1.

Presence of measurable disease as defined by RECIST version 1.1 Cohort 3: Patient Population: Relapsed/Refractory Triple Negative Breast Cancer

Presence of measurable disease as defined by RECIST version 1.1 Cohort 4: Patient Population: Relapsed/Refractory Ovarian Cancer

Presence of measurable disease as defined by RECIST version 1.1

Measurable disease as per RECIST, version 1.1.

Has measurable disease per RECIST 1.1 as determined by investigator

At least one radiologically measurable lesion as per RECIST 1.1

Presence of measurable disease per RECIST version (v)1.1; target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment.

Phase 1a: measurable or non-measurable disease per RECIST v 1.1.

Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).

ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Part I dose escalation: Participants are required to have measurable disease per RECIST 1.1 within 4 weeks of study entry

Measurable disease per RECIST version (v)1.1

At least 1 measurable lesion by RECIST 1.1

Measurable disease, as defined by RECIST v1.1

Patients must have measurable or evaluable disease per RECIST 1.1 criteria

Measurable disease, as defined by RECIST v1.1. At least one lesion accessible for biopsy

Participant must have measurable disease outside the field of radiation as defined by RECIST 1.1

Patients must have measurable disease as per RECIST (version 1.1)

Must have measurable disease per RECIST v1.1 Response Criteria

Measurable or evaluable disease by RECIST v1.1

Progressive disease defined by RECIST criteria =< 14 months

INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of measurable or non-measurable disease by RECIST 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is required

Measurable disease by RECIST 1.1 criteria

Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion

Patients must have measurable disease by RECIST criteria version 1.1

Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.

For Part 1, cohorts 1-3: evaluable disease (per RECIST version 1.1). For Part 1, cohorts 4-6 and Parts 2 and 3: measurable disease (per RECIST version 1.1)

Measurable disease per RECIST v1.1

Have measurable disease based on RECIST 1.1

Measurable disease per RECIST v1.1 by radiographic techniques

Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.

Measurable disease based on RECIST 1.1.

Part B (all cohorts): Have the presence of measurable disease as defined by the RECIST 1.1.

Presence of at least one measurable lesion according to RECIST v1.1.

Tumor measurable by RECIST 1.1 including >= 1 target lesion not planned for biopsy

Measurable tumor lesions according to RECIST 1.1 criteria (Section 10.2).

Presence of at least one measurable lesion according to RECIST v1.1.

Evaluable disease per RECIST 1.1

Measurable disease by RECIST 1.1 criteria

Evaluable/measurable disease by RECIST

Radiographically measurable disease by RECIST v1.1

Measurable disease by RECIST 1.1

PHASE IB: Measurable disease according to RECIST v1.1

Measurable disease by physical examination or imaging as defined by RECIST v1.1 criteria or evaluable disease as defined by Gynecologic Cancer Intergroup (GCIG) CA125 criteria.

Presence of at least one measurable lesion as defined by RECIST 1.1

Measurable disease as per RECIST v1.1 criteria

Radiologically measurable and clinically evaluable disease as per RECIST v1.1

Measurable disease, according to RECIST, v1.1

Patients must have at least 1 measurable metastatic lesion by RECIST1.1 criteria

Have measurable disease per RECIST version 1.1.

Evaluable or measurable disease as defined by RECIST v1.1 may be enrolled in the dose escalation part; for the dose confirmation part, subjects must have measurable disease by RECIST v1.1 or biomarker for response.

Patient with a TP53wt locally advanced or metastatic solid malignancy and with measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1 criteria.

Patients must have measurable disease according to RECIST 1.1

PART II: Patients must have measurable disease, per RECIST 1.1

Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1.

Measurable disease as outlined in RECIST 1.1

Patients must have metastatic disease, per RECIST 1.1 for the evaluation of measurable disease.

Have measurable disease based on RECIST 1.1. (in addition to the lesion/s that will be treated with stereotactic radiation therapy)

Have measurable disease, as defined by RECIST version 1.1;

Measurable disease, defined as per RECIST 1.1 criteria

Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.

Measurable disease per RECIST 1.1

Have at least one measurable lesions in the liver or at least one measurable lesion in the liver and another measurable lesion elsewhere, based on RECIST version (v.) 1.1

Must have evaluable or measurable disease per RECIST 1.1

Measurable disease, as defined by RECIST v1.1

Metastatic and/or unresectable (cT4b) urothelial cancer. Measurable disease according to RECIST 1.1 within 30 days prior to registration.

Measurable disease per RECIST version 1.1.

Measurable disease by RECIST 1.1

Measurable disease according to RECIST 1.1.

Have measurable disease based on RECIST 1.1

Have measurable disease per RECIST 1.1 criteria present

Has measurable disease based on RECIST version1.1

Have measurable disease based on RECIST 1.1

COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients must have measurable disease, per RECIST 1.1

COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients must have measurable disease, per RECIST 1.1

COHORT 3: ENDOMETRIAL CANCER: Patients must have measurable disease, per RECIST 1.1

Measurable disease as defined by RECIST 1.1

Subjects must have measurable disease according to RECIST (version 1.1)

Histologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version 1.1.

Measurable disease as defined by RECIST 1.1

Have measurable disease per RECIST version (v)1.1

Evaluable disease by RECIST v1.1.

Measurable or non-measurable disease, as defined by RECIST 1.1

Have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor response

Have measurable disease based on RECIST 1.1

Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1

Measurable disease based on RECIST 1.1.

Presence of measurable disease by RECIST 1.1

Participants must have measurable disease by RECIST version 1.1

Presence of measurable disease per RECIST v1.1.

Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.

Histologically confirmed advanced refractory solid tumor that is measurable or evaluable per RECIST 1.1 criteria.

Have measurable disease based on RECIST 1.1

Measurable disease by RECIST

Measurable disease as defined by RECIST v1.1

Have measurable disease based on RECIST 1.1

Patients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;

For disease-specific cohort participants: measurable disease per RECIST v. 1.1

Has at least one measurable lesion per RECIST version 1.1.

Measurable disease by per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of registration.

Phase 1: Participants must have either measurable or evaluable disease as per RECIST 1.1.

Phase 2: Participants must have measurable disease as per RECIST 1.1.

Have measurable disease based on RECIST 1.1

All patients enrolled will be required to have measurable disease by RECIST 1.1 criteria

At least one measurable lesion as defined by RECIST version 1.1; previously irradiated lesions are not measurable unless the lesion has demonstrated clear progression after radiation

Patient must have measurable disease based on RECIST 1.1 criteria

Have measurable disease per RECIST v1.1, assessed within 4 weeks prior to study entry

Measurable disease (RECIST 1.1)

Most recent imaging shows measurable disease as defined by RECIST 1.1

Patients must have measurable soft tissue disease per RECIST 1.1

Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v)1.1\r\n* NOTE: Scans must be =< 28 days prior to study treatment

Measurable disease according to RECIST v1.1 within 28 days prior to randomization

Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion

Measurable disease per RECIST 1.1

Have measurable clinical disease: measurable disease, defined as at least 1 measurable lesion on a computed tomography (CT) scan as defined by RECIST (version v1.1)

At least one index lesion that will not undergo RT or ablation, and which is measurable based on RECIST 1.1

Evaluable or measurable disease based on RECIST 1.1 (50)

Patients must have measurable disease as defined by RECIST v1.1

Measurable disease (> 10 mm) and have progression of disease based on RECIST criteria; previously irradiated tumor lesions are not considered measurable unless they have progressed since radiation

Measurable disease according to RECIST 1.1 within 28 days prior to registration.

Radiologically measurable disease in the pancreas >= 1 cm, as defined by RECIST v1.1

Measurable disease by RECIST 1.1 criteria

Measurable disease by RECIST 1.1

Patients with the presence of at least one measurable lesion as defined by RECIST 1.1 criteria for response assessment

Patients must have measurable disease by RECIST criteria

At least one measurable lesion based on RECIST version 1.1

FULL STUDY INCLUSION CRITERIA: Patients must have at least 1 measurable lesion according to RECIST version (v) 1.1

Measurable disease by CT or MRI as per RECIST 1.1. Bone-only disease is not permitted.

Measurable disease per RECIST v.1.1

Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.

Measurable disease according to RECIST 1.1.

Measurable disease per RECIST 1.1 (primary or metastases)

Have measurable disease based on RECIST 1.1

Has measurable disease based on RECIST v1.1 criteria

Have measurable disease per RECIST 1.1 criteria present

Measurable disease as defined by RECIST criteria (version 1.1)

Measureable disease according to RECIST Version 1.1

Patients must have measurable disease as defined by RECIST (see Section 6).

Measurable disease, according to modified RECIST 1.1 and irRECIST

Have measurable disease per RECIST 1.1 or irRECIST criteria present

All patients must have measurable disease as defined by RECIST 1.1; patients must also have evidence of disease progression by RECIST 1.1 within 6 months of first dose of study drug

Patients must have at least 1 lesion that is measurable using RECIST guidelines\r\n* NOTE: A previously irradiated lesion can be considered a target lesion if the lesion is well defined, measurable per RECIST, and has clearly progressed\r\n* NOTE: For patients with infiltrative disease, evaluable disease needs to be confirmed by pathology if RECIST measurements cannot be made

Measurable metastatic sites of disease outside of the target lesion undergoing palliative radiation based on RECIST 1.1 as assessed by the investigator

Have measurable or evaluable disease based on RECIST 1.1

Measurable disease as per the RECIST criteria v 1.1

Measurable and/or evaluable disease as per the RECIST criteria version (v) 1.1

Patients must have measurable disease according to RECIST 1.1

Patients must have at least one measurable lesion as defined per RECIST 1.1

Have measurable disease based on RECIST 1.1

Subjects must have measurable disease as defined by RECIST 1.1

Have measurable disease based on RECIST 1.1

Have measurable disease based on RECIST v.1.1

Measurable disease according to PET Response Criteria, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria

Patients may have measurable or non-measurable disease as defined by RECIST 1.1.

At least 1 measurable lesion (as per RECIST v1.1) progressing or new since last anti-tumor therapy.

Measurable target tumors using standard imaging techniques (RECIST version [v.] 1.1 criteria)

CERITINIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1

REGORAFENIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1

ENTRECTINIB INCLUSION CRITERIA: Measurable disease by RECIST v1.1

Have measurable disease based on RECIST 1.1.

Measurable or evaluable disease by RECIST v1.1 (not required for the cPoP study)

At least one measurable lesion as defined by RECIST 1.1

At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST 1.1

Radiographically measurable or evaluable disease per RECIST v1.1.

At least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated

Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment.

Have measurable disease based on RECIST 1.1 and immune related response (irRC) criteria

PHASE II: Patients must have measurable disease based on RECIST 1.1 criteria

Measurable disease by RECIST 1.1

Measurable disease as defined by RECIST 1.1 Criteria.

Have evaluable disease by RECIST 1.1 and PCWG2 criteria

CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease

Patients must have disease that is measurable by RECIST version 1.1

Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria

Presence of at least one measurable lesion according to RECIST v.1.1

Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)

Radiographically measurable disease per RECIST 1.1

Measurable tumor lesions according to RECIST 1.1 criteria.[22]

Patients may have measurable or non-measurable disease as defined by RECIST 1.1.

Patient must have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor response

Disease must be measurable by RECIST 1.1

Measurable or nonmeasurable disease by RECIST criteria (at least one target or nontarget lesion)

Patients must have measurable disease as per RECIST v1.1

Radiographically measurable per RECIST v1.1.

At least one measurable lesion of the disease on imaging (CT or MRI; RECIST 1.1)

Phase II cohorts only: patients must have measurable disease according to RECIST v.1.1 criteria. Patients enrolled in Ph Ib cohorts must have evaluable disease

Subject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.

Has evaluable or measurable disease by RECIST v1.1 criteria

Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.

At least one measurable/evaluable lesion by RECIST v1.1

Measurable or evaluable disease per RECIST v1.1

Patient has evaluable disease by RECIST v1.1 (Appendix 3).

Measurable disease as defined by RECIST version 1.1 by radiologic methods on or after the most recent line of therapy. For Cohort 2, imaging must be available for central review.

Existence of measurable or evaluable disease (as per RECIST 1.1 criteria).

Measurable disease by CT or MRI, as defined by RECIST v1.1

Current progressive disease, as defined by RECIST v1.1

Measurable or evaluable disease according to RECIST v1.1.

Has ?1 measurable lesion as defined by RECIST 1.1 on imaging studies.

At least one measurable lesion as defined by RECIST 1.1

Subject has at least one measurable lesion according to RECIST 1.1.

Part 2 only: have measureable disease by RECIST

Measurable disease as defined by RECIST v1.1 or disease-specific criteria for prostate cancer and malignant pleural mesothelioma

Patients must have at least one measurable or non-measurable lesion (dose escalation only) as defined by RECIST v1.1

In Stage 1, evaluable disease per RECIST 1.1. In Stage 2, measurable disease.

At least one radiologically measurable target lesion per RECIST version 1.1

Measurable tumor lesions according to RECIST 1.1 criteria.

Patients must have at least one measurable lesion per RECIST 1.1 criteria.

Patient with measurable disease according to RECIST

Measurable disease (revised RECIST; Version 1.1)

Measurable disease (revised RECIST; Version 1.1)

At least 1 unirradiated target lesion measurable by RECIST

Patients must have measurable disease by the Modified RECIST criteria

patients with NSCLC, UC, mBC, or SCCHN must have measurable disease by RECIST v1.1 criteria with at least one uni-dimensional measurable lesion;

Patients must have measurable disease based on RECIST 1.1, as determined by the site, to be eligible

Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology

Measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.

For Part 2, measurable disease as defined by RECIST, Version 1.1 including bone-only disease

Measurable Disease by RECIST v1.1

Measurable disease defined by RECIST criteria

Measurable disease according to RECIST v1.1.

Measurable disease per RECIST v1.1 for patients with solid malignancies.

Measurable disease, according to RECIST v1.1. Note that lesions intended to be biopsied should not be target lesions

Patients must have measurable disease as defined by RECIST 1.1 criteria

For dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1). For dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy.

Patients must have measurable disease in at least 2 non-radiated sites as defined by RECIST v1.1; all sites must be evaluated within 4 weeks prior to beginning therapy

Must have baseline measurable or evaluable disease per RECIST

Have measurable and/or evaluable disease by RECIST 1.1

Measurable disease by RECIST 1.1 guidelines

Patient has either measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion must be present

For the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesion

Absence of RECIST, v. 1.1 defined measurable disease.

Measurable disease as assessed by modified RECIST for MPM for thoracic disease (Appendix A) and RECIST 1.1 for extra-thoracic disease (Appendix B).

Measurable disease as per RECIST 1.1 criteria.

Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomization

Have measurable disease outside of biopsy site present per immune related (ir)RECIST criteria

Measurable and/or non-measureable disease by RECIST criteria must be present

Measurable disease according to RECIST 1.1 within 30 days prior to registration.

Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN])

Patients must have measurable disease based on RECIST 1.1

Participants must have measurable disease by RECIST 1.1

Participants must have at least a single (RECIST v1.1-defined) measurable lesion.

Triple negative breast cancer patients: participants may have either measurable disease via RECIST 1.1 criteria or evaluable disease

Measurable disease according to RECIST Version 1.1

At least one measurable site of disease in the liver according to RECIST version 1.1 and mRECIST criteria

Patients must measurable disease, as defined by RECIST 1.1 criteria

Presence of measurable disease according to RECIST 1.1

Patients must have measurable disease according to RECIST 1.1

COHORT EXPANSION PHASE: Patient must have measurable lesions as defined by RECIST version 1.1 criteria

Measurable disease per RECIST 1.1 criteria

Subjects must have measurable disease as defined by RECIST 1.1

PHASE II: Patients must have measurable disease based on RECIST 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration

Measureable disease according to RECIST Version 1.1

Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by computed tomography (CT) scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form

Patients must have at least one lesion that meets the definition of measurable disease by RECIST 1.1

Measurable disease according to RECIST v1.1

Measurable disease as per RECIST 1.1. Subject must have extracranial metastasis as measurable disease

Measurable disease as defined by RECIST 1.1

Radiographically documented measurable disease at study entry (as defined by the RECIST v1.1 criteria).

Measurable disease as defined by RECIST version 1.1

Measurable disease based on RECIST v1.1.

Has measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment.

Measurable lesions by RECIST v1.1

Patients must have measurable disease according to RECIST (v.1.1).

Measurable disease, as defined by RECIST Version 1.1 (v1.1).

Measurable disease by investigator assessment with at least 1 unidimensional measurable lesion by RECIST v.1.1 that has not previously been irradiated

Patient has either measurable disease per RECIST 1.1 criteria OR at least one predominantly lytic bone lesion must be present

Radiologically measurable disease according to RECIST v1.1

Measurable disease per RECIST v1.1

At least one site of disease that is measurable by RECIST (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation

Phase I (Cohort X): Participants with PIK3CA-mutant tumors and measurable disease per RECIST v1.1

One or more tumors measurable on CT scan per RECIST 1.1.

Measurable disease (at least one target lesion) according to RECIST v1.1

Measurable Disease per RECIST 1.1 as determined by the Investigator

Presence of measurable disease based on RECIST v1.1.

Measurable disease on CT or MRI by RECIST 1.1.

Measurable disease by RECIST

At least one extra-renal measurable target lesion meeting the criteria of RECIST version 1.1

Has measurable disease per RECIST 1.1 as assessed by BICR.

Has measureable or nonmeasurable disease as defined by RECIST 1.1 criteria.

Subject must have either measurable disease or bone only non measurable disease, according to RECIST1.1

Measurable disease according to RECIST v1.1

Measurable disease according to RECIST version 1.1.

Subjects must have measureable disease according to RECIST (version 1.1).

Measurable/assessable disease, as defined by RECIST v1.1.

Participants must have measurable disease that is evaluable as per RECIST v1.1

Has measurable disease per RECIST 1.1 as assessed by the investigator/site radiologist.

Measurable disease per RECIST 1.1 guidelines.

Measurable disease based on RECIST 1.1

Have measurable disease per RECIST 1.1 criteria

Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST Version 1.1 (including skin lesions)

Measurable disease per RECIST v1.1

Subjects with solid tumors, with the exception of CRPC, must demonstrate measurable disease, per RECIST v1.1. NOTE: Subjects with NMC that do not meet the RECIST v1.1 criteria for measurable disease, but have evaluable disease may be considered for enrollment after discussion with the GSK medical monitor..

Measurable disease per RECIST v1.1

Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v.) 1.1

Has measurable disease based on either modified RECIST [Nowak 2005] for thoracic disease or RECIST 1.1 elsewhere

Measurable disease, as defined by RECIST v1.1

Have at least 1 measurable (i.e., target) lesion per RECIST v1.1.

Measurable disease according to RECIST 1.1 criteria.

At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1

Measurable disease via RECIST v1.1 or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1

At least one measureable lesion by RECIST 1.1.

Patients must have measurable disease as defined by RECIST 1.1.

Measurable disease as defined by RECIST 1.1

The subject has measurable disease or nonmeasurable, evaluable disease per RECIST 1.1. (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST 1.1).

Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v.) 1.1

Measurable disease by RECIST 1.1 criteria

Measurable disease defined as at least one uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1

Measurable disease based on RECIST v1.1.

Measurable disease based on RECIST v1.1.

Measurable disease based on RECIST v1.1.

Measurable disease as defined by modified RECIST for MPM (Byrne and Nowak, 2004)

Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation; the pleural mesothelioma cohort will require measurable disease according to modified RECIST

Previous exposure to murine CA-125 antibody (only applicable to those patients with non-measurable disease by RECIST)

Measurable disease according to RECIST v1.1

Measurable disease per RECIST v1.1

Patients must have at least 1 lesion that is measurable using RECIST guidelines.

Have measurable disease based on RECIST 1.1

Measurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria.

Have measureable disease per RECIST 1.1.

Patient must have either measurable disease by RECIST 1.1 or at least one predominantly lytic bone lesion.

Subjects must have measurable disease as defined per RECIST Version 1.1.

Measurable disease as defined by RECIST v1.1

Presence of at least one measurable lesion according to RECIST v.1.1

Disease must be measurable by RECIST 1.1

Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1.

Demonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version 1.1 is NOT required for enrollment)

Measurable disease, according to the RECIST v1.1

Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria

At least one radiographically measurable lesion per RECIST 1.1

Disease must be measurable by RECIST 1.1 criteria

Non-measurable disease according to RECIST 1.1, with the exception of bone-only non-measurable disease.

Subjects must have at least 1 measurable lesion based on RECIST version 1.1.

Measurable disease as defined by RECIST 1.1

Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1

Measurable disease defined by RECIST version 1.1, or bone-only disease

Patients must have at least one measurable site of disease (according to RECIST [version 1.1] criteria)

Patients must not have measurable progressive disease (RECIST 1.1)

Patients must have at least one measurable site of disease according to RECIST version 1.1 criteria

Subjects must have at least 1 extracranial, unresectable, non-bony lesion that is measurable radiographically (based on RECIST 1.1)

Measurable disease per RECIST v1.1 (see Appendix 3)

Presence of measurable disease per RECIST v1.1.

Cancer antigen-125 (CA-125) only disease without RECIST 1.1 measurable disease

Measurable disease in accordance with RECIST version 1.1

Does not have measurable disease per RECIST 1.1

Measurable disease per RECIST 1.1 criteria

Disease must be measurable by RECIST 1.1

At least 1 target lesion that is measurable by RECIST, Version 1.1

Measurable disease according to RECIST 1.1.

Participants must have measurable disease by RECIST 1.1 criteria

Measurable disease per RECIST v1.1.

Have measurable disease based on RECIST 1.1

At least one index lesion that will not undergo RT and which is measurable based on RECIST 1.1

Patients must have measurable disease according to the standard RECIST version 1.1; CT scans or magnetic resonance imaging (MRIs) used to assess the measurable disease must have been completed within 28 days prior to registration

Measurable disease on CT or MRI scan by RECIST criteria (required for Phase 1b only).

Evidence of measurable disease per RECIST 1.1

Participants must have measurable disease by RECIST v1.1 or non-measurable, evaluable disease with atleast one evaluable bone lesion by RECIST v1.1 based on radiologic scans within 28 days of Day 1 of Cycle 1

Measurable non-CNS disease, defined by RECIST 1.1 criteria

Measurable disease as defined by RECIST 1.1.

Patients must have measurable disease, defined by RECIST 1.1

At least 1 target lesion that is measurable by RECIST, Version 1.1

At least one measureable lesion as defined by RECIST version 1.1 that has not been previously irradiated.

Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1.

Presence of radiographically measurable disease as defined by RECIST 1.1

At least one index lesion that will not undergo RT or ablation, and which is measurable based on RECIST 1.1

Have measurable and/or evaluable disease based on RECIST 1.1.

Patients must have one or more tumors measurable on radiographic imaging as defined by RECIST.

Have measurable disease according to RECIST v1.1 obtained by imaging within 28 days prior to registration.

Measurable disease of at least 2 cm and otherwise based on RECIST 1.1, assessed from MRI scans by a central radiologist.

Measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, and obtained by imaging within 28 days prior to registration for protocol therapy.

Radiographically measurable disease acc. to RECIST 1.1

Measurable disease according to the RECIST criteria (version 1.1), for the evaluation of measurable disease

Patient has measurable disease, as determined by the Investigator using RECIST, version 1.1, as determined within 28 days before baseline (C1D1).

Measurable disease, as defined by RECIST v1.1

Measurable disease as per RECIST v1.1

Subject must have at least 1 unidimensional measurable NSCLC lesion on a CT scan as defined by RECIST (version 1.1).

Measurable disease based on RECIST 1.1 as determined by central review

Radiographically-measurable disease based on RECIST 1.1

Subjects must have at least one measurable lesion per RECIST 1.1

Measurable disease, as defined by RECIST v1.1

Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).

Measurable disease as defined by RECIST 1.1 criteria;

Measurable (RECIST) indicator lesion not previously irradiated.

Measurable disease, as defined by RECIST version 1.1

Measurable disease as assessed by modified RECIST for MPM and by RECIST 1.1 criteria for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid carcinoma

Measurable or evaluable disease by RECIST 1.1

Measurable disease, as defined by RECIST v 1.1

Has at least 1 radiologically measurable lesion as defined by RECIST 1.1

Measurable disease by RECIST 1.1 criteria

Presence of at least 1 measurable lesion according to RECIST version 1.1

PART B: Patients must have measurable disease as per RECIST version 1.1

Presence of at least one measurable lesion per RECIST 1.1 criteria

Presence of measurable lesions (RECIST V1.1)

At least one measurable lesion as defined by modified RECIST version 1.1; previously irradiated lesions are not measurable unless the lesion is new or has demonstrated clear progression after radiation

Measurable or evaluable non-measurable disease as assessed by the investigator according to RECIST v1.1 criteria

Measurable disease as defined by RECIST Criteria.

At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST (RECIST version 1.1), and modified RECIST for HCC. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.

Evaluable disease as determined by RECIST 1.1

Measurable disease as defined by RECIST v1.1

Measurable disease according to modified RECIST version 1.1

Measurable disease according to RECIST 1.1

Must have measurable disease as defined by RECIST 1.1.

Patient has measurable disease by (RECIST).

Have evidence of measurable disease as defined by RECIST Version 1.1

Measurable disease as defined by RECIST 1.1 criteria

Measurable disease according to RECIST version 1.1

Measurable disease according to RECIST v1.1

Measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by RECIST 1.1

Measurable disease by RECIST version 1.1

Has measurable disease per RECIST 1.1 as determined by the local site investigator/radiology assessment

Patients must have RECIST v1.1 measurable disease

Measurable disease per RECIST 1.1 as determined by the investigator.

Disease must be measurable, with ?1 unidimensional measurable lesion per RECIST 1.1.

Has ?1 lesion that meets the criteria for measurable, as defined by RECIST 1.1, and is appropriate for selection as a target lesion, as determined by local site investigator/radiology assessment

Measurable disease by RECIST 1.1 criteria

Participants in the Phase II portion of the trial must have measurable disease by RECIST 1.1 criteria

Breast cancer participants must have measurable disease by RECIST criteria

For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:

Patients must have measurable disease (at least one measurable lesion) as defined by RECIST criteria; all sites of disease must be evaluated within 4 weeks prior to registration to treatment

Measurable disease as per RECIST v. 1.1.

Subject must have at least 1 measureable lesion based on RECIST V1.1. Previously irradiated lesions will not be considered as measurable lesions.

Presence of measurable disease per RECIST v1.1

Measurable disease according to RECIST v 1.1 obtained by imaging within 28 days prior to registration

Measurable disease by RECIST version 1.1.

Subjects must have either measurable disease or bone-only non-measurable disease, evaluable according to RECIST 1.1

Measurable disease as per RECIST 1.1

Measureable disease according to RECIST Version 1.1

Measurable disease according to RECIST 1.1

Measurable disease by CT or MRI per RECIST 1.1 criteria

Measurable disease per RECIST v1.1 (see Appendix 6)

Radiographic progression in soft tissue or bone by modified RECIST 1.1 for subjects with measurable disease; or

Measurable disease by RECIST 1.1 criteria.

Evaluable or measurable disease, as assessed by RECIST v1.1

Tumors must have measurable disease as per RECIST (version 1.1);

Measurable disease per RECIST v1.1

At least 1 measurable lesion as defined by RECIST v1.1

Measurable disease by RECIST 1.1

Measurable disease per RECIST v1.1

Measurable disease as per RECIST v1.1

At least one lesion measurable by RECIST not previously irradiated (Monotherapy and in Cohorts A and B)

Measurable disease at screening by RECIST 1.1 criteria

Radiographically measurable or evaluable disease (per RECIST v1.1)

Measurable disease per RECIST v1.1

Subjects may have measurable or non-measurable disease according to RECIST 1.1.

Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1

3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.

At least 1 site of disease measurable by RECIST ver1.1

At least one measurable or non-measurable lesion as per RECIST 1.1 criteria for patients in Phase Ib; Measurable disease as determined by RECIST v1.1 for Phase II patients

Measurable disease that can be monitored per RECIST throughout the course of study participation.

Measurable disease according to RECIST Version 1.1 or non-measurable evaluable disease

At least one measurable lesion by CT scan or MRI based on RECIST version 1.1

Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1;

Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease.

Have measurable disease based on RECIST 1.1

Presence of measureable disease based on RECIST v1.1

Patient must have measurable lesions as defined by RECIST version 1.1 criteria

Measurable disease (per RECIST v1.1) prior to the start of first-line chemotherapy

Have a measurable disease based on RECIST 1.1.

Measurable disease by RECIST 1.1

Measurable disease as per RECIST 1.1

Evaluable or measurable disease per RECIST v1.1

Disease that is measurable per RECIST v1.1

Radiologically measurable and clinically evaluable disease as per RECIST v1.1

Measurable disease according to RECIST criteria (Version 1.1)

Patients must have measurable disease according to RECIST 1.1, and have relapsed or become refractory to conventional therapy

Measurable disease as defined by RECIST v1.1

Measurable disease by RECIST v1.1 with at least one measurable target lesion

Evaluable or measurable disease per RECIST v1.1

Evaluable or measurable disease per RECIST v1.1

Measurable disease as defined by RECIST v1.1

Measurable disease, as determined by radiologist evaluator, with at least 1 unidimensional measurable lesion (target lesion) by RECIST v.1.1 that has not previously been irradiated or biopsied

Measurable disease per RECIST 1.1

Patients must have measurable disease per RECIST criteria version (v.) 1.1

For expansion: documentation by established staging studies or clinical examination to have measurable metastatic disease per RECIST v1.1 criteria

At least one lesion measurable by RECIST Version 1.1.

Measurable disease, as defined by RECIST v1.1; previously irradiated lesions can be counted as target lesions if clearly progressing after radiation

Patients must have measurable disease defined by RECIST criteria 1.1.

Measurable disease by RECIST v1.1 criteria

Measurable lesion by RECIST 1.1

ECOG performance status 0 or 1 5. Measurable disease per RECIST v1.1

Measurable disease as per RECIST v1.1

Measurable or evaluable disease by RECIST 1.1

Measurable disease as per RECIST 1.1.

At least one measurable lesion per RECIST v1.1. However, breast cancer patients with only bone disease are also eligible.

Patient must have measurable disease per RECIST 1.1 presented after tumour biopsy for the late disease progression

Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.

Patient has progressive and measurable disease as per RECIST 1.1 or other appropriate hematological guidelines.

Measurable disease per RECIST v1.1.

Measurable disease per RECIST 1.1

Patients must have at least one measurable site of disease according to RECIST 1.1 that has not been previously irradiated

Measurable disease defined as one or more target lesions according to RECIST

Evaluable or measurable disease per RECIST v1.1

Measurable disease (i.e., present with at least one measurable lesion per RECIST, version 1.1).

Measurable tumor lesions according to RECIST 1.1 criteria.[50]

Measurable disease by RECIST

Must have measurable disease (RECIST v1.1) in at least one lesion not previously irradiated unless documented evidence of progression

At least 1 measurable lesion per RECIST v1.1; subjects whose only measurable lesion is a lymph node will be excluded

Evaluable or measurable disease per RECIST v1.1

Measurable disease as per RECIST Version 1.1 criteria.

Evaluable or measurable disease per RECIST v1.1

At least one measurable disease site per RECIST v1.1.

Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).

Measurable disease defined by RECIST v1.1

Have one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.

Patients must have presence of at least 1 lesion that is measurable or evaluable using RECIST v1.1.

Disease that is measurable per modified RECIST v1.1

Measurable disease using RECIST criteria (version 1.1).

Measurable radiographic evidence of disease according to RECIST v1.1

Measurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C.

Measurable disease (by RECIST 1.1)

Measurable disease according to RECIST v1.1 prior to administration of study drug

Measurable disease by RECIST 1.1 with PCWG2 modifications

Participants must have measurable disease defined as at least one target lesion that has not been irradiated and can be accurately measured in at least one dimension by RECIST v1.1 criteria.

Subject must have evaluable disease as per RECIST criteria.

Measurable disease as defined by the RECIST v1.1.

Measurable disease according to RECIST v1.1

Measurable disease by RECIST 1.1 criteria

Measurable disease as assessed by RECIST 1.1 criteria (Appendix A).

Measurable disease on baseline imaging per RECIST 1.1 criteria

Patients must have measurable disease as defined by revised RECIST criteria (version 1.1, Appendix C) with one or more lesions that can be accurately measured in one or more dimensions within 4 weeks of entry. Areas of previous radiation may not serve as measurable disease.

There is progression of disease documented by RECIST 1.1

Radiographically or clinically evaluable tumor. In the expansion phase, disease must be measurable according to RECIST 1.1.

Measurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST 1.1

Measurable disease per RECIST v 1.1

Measurable Disease per RECIST 1.1

Measurable disease by RECIST v1.1

Patient must have measurable disease as defined by RECIST 1.1.

Presence of measurable disease based on RECIST v1.1.

Patients with measurable disease per RECIST 1.1 criteria\r\n* At least one lesion of >= 1.5 cm in long-axis diameter for non lymph nodes or >= 1.5 cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)\r\n* Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesion

During the dose expansion part of study, all patients must have at least one measurable lesion as defined by RECIST criteria.

Measurable disease per RECIST v1.1

At least one measurable lesion and/or non-measurable disease evaluable according to RECIST v1.1 criteria

Measureable disease as per RECIST

Measurable disease per RECIST 1.1 criteria. Subjects with non-measurable, but evaluable disease are also eligible for Part 1 of the study.

Measurable disease as determined by RECIST 1.1

At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria

Measurable disease according to RECIST

Measurable disease at baseline in accordance with RECIST Version 1.1

Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.

Measurable disease as per RECIST guideline (Version 1.1);

Part A2 & B (RCC, NSCLC, HCC, and uveal melanoma): Have measurable disease as defined by RECIST v1.1.

Patients with measurable or non-measurable disease as determined by modified RECIST version 1.0 in dose-escalation phase, and patients with at least one measurable lesion as determined by RECIST 1.0 in expansion phase.

Measurable disease at presentation with disease measurable by RECIST required in the phase II cohort

Measurable disease according to RECIST version 1.1.

Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.

Evaluable disease or disease measurable per RECIST

Measurable disease per the RECIST criteria. For disease occurring in previously irradiated field, there must be confirmed progression prior to the date registration and more than three months after completion of radiotherapy

Measurable disease by RECIST 1.1

Patients must have measurable disease by RECIST 1.1 criteria

For the expansion cohort only: measurable disease by RECIST v1.1 with at least one measurable target lesion

At least one measurable lesion as defined by RECIST v1.1

Have measurable disease per RECIST v.1.1.

Measurable disease, as defined by RECIST 1.1 criteria;

Evaluable or measurable disease per RECIST, Version 1.1

Subject has measurable disease according to RECIST v1.1 criteria.

Cohort A: Patients must have at least one measurable visceral lesion (per RECIST 1.1); a visceral lesion is any solid organ except for skin, lymph node, and musculoskeletal tissue; at least one of these visceral lesions must be measurable per RECIST 1.1

Measurable disease per RECIST v1.1

Subjects must have at least one lesion that is measurable by RECIST v1.1

Measurable disease per RECIST 1.1 criteria

At least 1 measurable tumor lesion per RECIST v1.1 (exception: subjects in Part 1 are not required to present with measurable disease)

At least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1)

Measurable disease according to RECIST v1.1 criteria

Measurable disease at baseline as per RECIST version 1.1

Measurable disease as defined by RECIST v1.1

Measurable disease by RECIST criteria

Evidence of measurable disease by RECIST 1.1

Measurable disease as defined by RECIST 1.1 within 28 days prior to registration

Tumor to be irradiated as measurable by RECIST 1.1 or PRC

Patient must be evaluable using RECIST 1.1 criteria

Has at least one measurable lesion per RECIST version 1.1

Subject must have measureable disease by RECIST 1.1.

Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by RECIST criteria version (v)1.1

Measurable disease according to RECIST v1.1

Measurable disease according to RECIST 1.1 criteria.

Subjects must have measurable disease by RECIST Version 1.1.

Measurable disease by RECIST 1.1

With the exception of patients with non-measurable neuroblastoma patients must have measurable disease as per RECIST 1.1

Has At least one measurable lesion as defined by RECIST criteria

Presence of measurable (by RECIST v1.1) and active extracranial disease will be excluded; patients with measurable extra cranial disease by RECIST v1.1 will be eligible to enroll if sites of disease are stable and not considered to be active after discussion with the sponsor

Part 1, Dose Escalation: Participants may have measurable or non measurable disease as defined by RECIST 1.1/mRECIST (depending on tumor type).

Evaluable disease or disease measurable per RECIST 1.1

The participant has measurable or non-measurable disease according to RECIST 1.0 guidelines.

Presence of measureable disease based on RECIST v1.1.

Have measurable disease based on RECIST 1.1

To be enrolled in the dose escalation phase of the study, participants must have a radiographically or clinically evaluable tumor, but measurable disease as defined by RECIST version 1.1 [1] is not required for participation in this study.

Histologically confirmed, metastatic TNBC with measurable disease per RECIST version 1.1.

Measurable disease per RECIST version 1.1.

Measurable disease, as defined by RECIST v1.1

Patients must have measurable disease per RECIST v. 1.1.

Presence of measurable or non-measurable lesions as defined by irRC-RECIST

Disease must be evaluable as per RECIST 1.1 or RANO (for gliomas). At least one measurable target lesion is required in expansion cohort patients

Measurable disease as per RECIST v1.1 criteria

Presence of measureable disease based on RECIST v1.1